Cite
Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes.
MLA
Geiger, Mary Jane, et al. “Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes.” Therapeutic Innovation & Regulatory Science, vol. 49, no. 1, Jan. 2015, pp. 50–64. EBSCOhost, https://doi.org/10.1177/2168479014549860.
APA
Geiger, M. J., Mehta, C., Turner, J. R., Arbet-Engels, C., Hantel, S., Hirshberg, B., Koglin, J., Mendzelevski, B., Sager, P. T., Shapiro, D., Stewart, M., Todaro, T. G., & Gaydos, B. (2015). Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes. Therapeutic Innovation & Regulatory Science, 49(1), 50–64. https://doi.org/10.1177/2168479014549860
Chicago
Geiger, Mary Jane, Cyrus Mehta, J. Rick Turner, Christophe Arbet-Engels, Stefan Hantel, Boaz Hirshberg, Joerg Koglin, et al. 2015. “Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes.” Therapeutic Innovation & Regulatory Science 49 (1): 50–64. doi:10.1177/2168479014549860.